Back to Search
Start Over
Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
- Source :
- Tuberculosis and Respiratory Diseases, Vol 84, Iss 2, Pp 96-104 (2021), Tuberculosis and Respiratory Diseases
- Publication Year :
- 2021
- Publisher :
- The Korean Academy of Tuberculosis and Respiratory Diseases, 2021.
-
Abstract
- Background: Many chronic obstructive pulmonary disease (COPD) patients receiving monotherapy continue to experience symptoms, exacerbations and poor quality of life. This study aimed to assess the efficacy and safety of direct switch from once-daily tiotropium (TIO) 18 μg to indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily in COPD patients in Korea. Methods: This was a randomized, open-label, parallel group, 12-week trial in mild-to-moderate COPD patients who received TIO 18 μg once daily for ≥12 weeks prior to study initiation. Patients aged ≥40 years, with predicted post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥50%, post-bronchodilator FEV1/forced vital capacity
- Subjects :
- Pulmonary and Respiratory Medicine
Long-Acting β2-Agonist
medicine.medical_specialty
Vital capacity
long-acting β-agonist
korea
Pulmonary disease
indacaterol/glycopyrronium
tiotropium
Internal medicine
medicine
COPD
long-acting muscarinic antagonist
Lung function
lcsh:RC705-779
biology
business.industry
lung function
lcsh:Diseases of the respiratory system
Lama
medicine.disease
Rescue medication
biology.organism_classification
Safety profile
Infectious Diseases
Indacaterol
Original Article
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 20056184 and 17383536
- Volume :
- 84
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Tuberculosis and Respiratory Diseases
- Accession number :
- edsair.doi.dedup.....05302d8f5cc80a69e8a733ed27811b89